JP2024521316A - 非ペプチド標的治療薬及びその使用 - Google Patents

非ペプチド標的治療薬及びその使用 Download PDF

Info

Publication number
JP2024521316A
JP2024521316A JP2023572689A JP2023572689A JP2024521316A JP 2024521316 A JP2024521316 A JP 2024521316A JP 2023572689 A JP2023572689 A JP 2023572689A JP 2023572689 A JP2023572689 A JP 2023572689A JP 2024521316 A JP2024521316 A JP 2024521316A
Authority
JP
Japan
Prior art keywords
receptor
cancer
compound
unsubstituted
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521316A5 (enExample
Inventor
ストラザーズ，アール．，スコット
ジャオ，ジェン
ヂュ，ユンフェイ
Original Assignee
クリネティックス ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリネティックス ファーマシューティカルズ，インク． filed Critical クリネティックス ファーマシューティカルズ，インク．
Publication of JP2024521316A publication Critical patent/JP2024521316A/ja
Publication of JP2024521316A5 publication Critical patent/JP2024521316A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023572689A 2021-06-09 2022-06-08 非ペプチド標的治療薬及びその使用 Pending JP2024521316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208923P 2021-06-09 2021-06-09
US63/208,923 2021-06-09
PCT/US2022/032707 WO2022261235A1 (en) 2021-06-09 2022-06-08 Non-peptide targeted therapeutics and uses thereof

Publications (2)

Publication Number Publication Date
JP2024521316A true JP2024521316A (ja) 2024-05-31
JP2024521316A5 JP2024521316A5 (enExample) 2025-06-16

Family

ID=84425531

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023572689A Pending JP2024521316A (ja) 2021-06-09 2022-06-08 非ペプチド標的治療薬及びその使用
JP2023576169A Pending JP2024521450A (ja) 2021-06-09 2022-06-08 非ペプチド標的治療およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023576169A Pending JP2024521450A (ja) 2021-06-09 2022-06-08 非ペプチド標的治療およびその使用

Country Status (5)

Country Link
US (2) US20240408247A1 (enExample)
EP (2) EP4351653A4 (enExample)
JP (2) JP2024521316A (enExample)
CN (1) CN117377495A (enExample)
WO (2) WO2022261221A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023396827A1 (en) * 2022-12-13 2025-06-19 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
TW202613146A (zh) * 2024-06-11 2026-04-01 美商克林提克斯醫藥股份有限公司 生長抑素亞型-2受體(sst2r)非肽藥物偶聯物及其用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004002309A (ja) * 2002-02-12 2004-01-08 Pfizer Inc 非ペプチドＧｎＲＨ剤、医薬組成物、及びそれらの使用方法
JP2004519449A (ja) * 2000-12-27 2004-07-02 バイエル アクチェンゲゼルシャフト 特異的開裂性結合単位を有するインテグリン受容体拮抗薬と細胞増殖抑制剤との複合体
JP2005501006A (ja) * 2001-06-06 2005-01-13 アグロン・ファーマシューティカルズ・インコーポレーテッド 非ペプチドＧｎＲＨ薬、医薬組成物、その利用法、これら物質とその中間体の調製方法
JP2006510571A (ja) * 2002-03-01 2006-03-30 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 治療剤または細胞毒性剤と生物活性ペプチドとの抱合体
JP2007527421A (ja) * 2004-02-23 2007-09-27 ジェネンテック・インコーポレーテッド 複素環式自壊的リンカーおよび結合体
JP2007538099A (ja) * 2004-05-19 2007-12-27 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
WO2014184682A1 (en) * 2013-04-19 2014-11-20 Oslo Universitetssykehus Hf Radiolabeled gnrh antagonists as pet imaging agents
WO2015151079A2 (en) * 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Auristatin analogues and their conjugates with cell-binding molecules
JP2016501859A (ja) * 2012-11-24 2016-01-21 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
JP2020511452A (ja) * 2017-03-16 2020-04-16 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレータとその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405906B (de) * 1997-03-14 1999-12-27 Irene Dr Virgolini Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
CN100356984C (zh) * 2002-01-24 2007-12-26 巴内斯－朱威胥医院 整联蛋白靶向的影像剂
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
CA2925651A1 (en) 2013-09-30 2015-04-02 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
CA3050094C (en) * 2017-01-12 2024-01-02 Radiomedix Inc. Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
MX2019009419A (es) 2017-02-08 2019-10-02 Ono Pharmaceutical Co Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo.
KR102724812B1 (ko) * 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
TWI852944B (zh) 2018-09-18 2024-08-21 美商克林提克斯醫藥股份有限公司 生長抑制素(somatostatin)調節劑及其用途

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004519449A (ja) * 2000-12-27 2004-07-02 バイエル アクチェンゲゼルシャフト 特異的開裂性結合単位を有するインテグリン受容体拮抗薬と細胞増殖抑制剤との複合体
JP2005501006A (ja) * 2001-06-06 2005-01-13 アグロン・ファーマシューティカルズ・インコーポレーテッド 非ペプチドＧｎＲＨ薬、医薬組成物、その利用法、これら物質とその中間体の調製方法
JP2004002309A (ja) * 2002-02-12 2004-01-08 Pfizer Inc 非ペプチドＧｎＲＨ剤、医薬組成物、及びそれらの使用方法
JP2006510571A (ja) * 2002-03-01 2006-03-30 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 治療剤または細胞毒性剤と生物活性ペプチドとの抱合体
JP2007527421A (ja) * 2004-02-23 2007-09-27 ジェネンテック・インコーポレーテッド 複素環式自壊的リンカーおよび結合体
JP2007538099A (ja) * 2004-05-19 2007-12-27 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
JP2016501859A (ja) * 2012-11-24 2016-01-21 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
WO2014184682A1 (en) * 2013-04-19 2014-11-20 Oslo Universitetssykehus Hf Radiolabeled gnrh antagonists as pet imaging agents
WO2015151079A2 (en) * 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Auristatin analogues and their conjugates with cell-binding molecules
JP2020511452A (ja) * 2017-03-16 2020-04-16 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレータとその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI, HAITAO, ET.AL.: "Discovery of a Novel, Orally Active, Small Molecule Gonadotropin-Releasing Hormone (GnRH) Receptor A", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49(11), JPN6026006170, 2006, pages 3362 - 3367, ISSN: 0005798769 *
LIMONTA, PATRIZIA, ET AL.: "GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies", ENDOCRINE REVIEWS, vol. 33(5),, JPN6026006176, 2012, pages 784 - 811, ISSN: 0005798768 *

Also Published As

Publication number Publication date
EP4351653A1 (en) 2024-04-17
EP4351653A4 (en) 2025-11-12
JP2024521450A (ja) 2024-05-31
WO2022261235A1 (en) 2022-12-15
CN117377495A (zh) 2024-01-09
WO2022261221A1 (en) 2022-12-15
US20240285628A1 (en) 2024-08-29
US20240408247A1 (en) 2024-12-12
EP4351654A4 (en) 2025-11-12
EP4351654A1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
US12466829B2 (en) Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US12479825B2 (en) Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US7807704B2 (en) Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
JP5284091B2 (ja) 成長ホルモン分泌促進受容体のグレリン類似体リガンドとしての新規のトリアゾール誘導体
TWI331922B (en) Growth hormone releasing peptides
CN112236442A (zh) 异源串联双环肽复合物
JP5960563B2 (ja) 胃腸運動を刺激するための組成物及び方法
TWI603967B (zh) 具有增進之受體活性及生物有效性性質之新穎三唑衍生物在用作生長激素促泌素受體之腦腸肽拮抗劑上之用途
KR20110093832A (ko) Ｃｘｃｒ4 수용체 화합물
EA027853B1 (ru) Синтетические миметики апелина для лечения сердечной недостаточности
KR20110091702A (ko) Ａｐｊ 수용체 화합물
US12134610B2 (en) Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof
WO2022261235A1 (en) Non-peptide targeted therapeutics and uses thereof
TW202409009A (zh) 黑素皮質素2型受體(mc2r)之靶向治療劑及其用途
US20250000988A1 (en) Epha2 bicyclic peptide ligand and conjugate thereof
KR20240117631A (ko) 아펠린성 거대고리 및 이의 용도
US20260007758A1 (en) Somatostatin subtype-2 receptor (sst2r) non-peptide drug conjugates and uses thereof
KR20030027439A (ko) 멜라노코틴 수용체의 항진제
RU2415134C2 (ru) Способ лечения или профилактики физиологических и/или патофизиологических состояний, опосредуемых рецепторами, стимулирующими секрецию гормона роста, триазолы и фармацевтическая композиция на их основе
TW202602908A (zh) 靶向綺思蛋白(kisspeptin)受體(kiss1r)之治療劑及其用途
KR20030035588A (ko) 멜라노코틴 수용체의 항진제
JPH09194500A (ja) ペプチド誘導体、その製造法および用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260507